Suppr超能文献

美国放射学会骨报告与数据系统™(ACR骨影像报告和数据系统™,ACR Bone-RADS™)对溶骨性骨肿瘤进行分类的验证。

Validation of the American College of Radiology Bone Reporting and Data System™ (ACR Bone-RADS™) for classifying osteolytic bone tumors.

作者信息

Kim Youngjune, Chee Choong Guen, Kang Yusuhn

机构信息

Department of Radiology, Seoul National University Bundang Hospital, 82 Gumi-Ro-173-Beon-Gil, Bundang-Gu, Seongnam-Si, Gyeonggi-Do, 13620, Republic of Korea.

Seoul National University College of Medicine, 103, Daehak-Ro, Jongno-Gu, Seoul, 03080, Republic of Korea.

出版信息

Skeletal Radiol. 2025 Feb 3. doi: 10.1007/s00256-025-04881-x.

Abstract

OBJECTIVE

To validate the performance of the American College of Radiology (ACR) Bone-RADS™ in identifying malignant osteolytic bone tumors and to evaluate the inter-observer agreement between musculoskeletal radiologists performing ACR Bone-RADS™ assessments.

METHODS

This single-center, retrospective study included patients who visited our orthopedic oncology department on January 2019-December 2020 for bone tumors. Three radiologists evaluated the initial radiographs and assessed whether the tumor was eligible for ACR Bone-RADS™ assessment considering its transverse location and radiodensity. For eligible tumors, the radiologists rated the descriptors of ACR Bone-RADS™ and calculated the Bone-RADS™ categories. Using multi-reader, multi-case analysis, the performance in identifying malignant bone tumors was assessed in terms of sensitivity and area under the receiver-operating-characteristic curve (AUC), while dichotomizing the Bone-RADS™ categories into potentially benign (categories 1-2) and potentially malignant (categories 3-4). Gwet's AC1 was calculated to evaluate inter-observer agreement on the categories. The proportion of malignancy in each Bone-RADS™ category was calculated.

RESULTS

In total, 278 patients (mean age ± standard deviation, 40 ± 22 years; 161 men; and 93 with malignant tumors) were eligible for assessment. The sensitivity and AUC for discriminating malignancy using ACR Bone-RADS™ were 95.0% and 0.915, respectively. There was moderate inter-observer agreement on the ACR Bone-RADS™ category, with a Gwet's AC1 of 0.594 (95% confidence interval, 0.536-0.652). The proportions of malignancy were 0.0-1.2% in Bone-RADS™ category 1; 4.0-9.0% in category 2; 18.2-30.3% in category 3; and 77.7-83.3% in category 4.

CONCLUSION

The ACR Bone-RADS™ showed high diagnostic performance in detecting malignant osteolytic bone tumors, with moderate inter-observer agreement.

摘要

目的

验证美国放射学会(ACR)骨影像报告和数据系统(Bone-RADS™)在识别恶性溶骨性骨肿瘤方面的性能,并评估进行ACR Bone-RADS™评估的肌肉骨骼放射科医生之间的观察者间一致性。

方法

这项单中心回顾性研究纳入了2019年1月至2020年12月因骨肿瘤就诊于我院骨科肿瘤科的患者。三名放射科医生评估了初始X线片,并根据肿瘤的横向位置和放射密度评估其是否符合ACR Bone-RADS™评估标准。对于符合标准的肿瘤,放射科医生对ACR Bone-RADS™的描述符进行评分并计算Bone-RADS™类别。采用多读者、多病例分析,以灵敏度和受试者工作特征曲线下面积(AUC)评估识别恶性骨肿瘤的性能,同时将Bone-RADS™类别分为可能良性(1-2类)和可能恶性(3-4类)。计算Gwet's AC1以评估观察者间在类别上的一致性。计算每个Bone-RADS™类别中的恶性肿瘤比例。

结果

共有278例患者(平均年龄±标准差,40±22岁;男性161例;93例患有恶性肿瘤)符合评估标准。使用ACR Bone-RADS™鉴别恶性肿瘤的灵敏度和AUC分别为95.0%和0.915。观察者间在ACR Bone-RADS™类别上的一致性为中等,Gwet's AC1为0.594(95%置信区间,0.536-0.652)。Bone-RADS™ 1类中的恶性肿瘤比例为0.0-1.2%;2类为4.0-9.0%;3类为18.2-30.3%;4类为77.7-83.3%。

结论

ACR Bone-RADS™在检测恶性溶骨性骨肿瘤方面表现出较高的诊断性能,观察者间一致性为中等。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验